161 related articles for article (PubMed ID: 38045662)
1. Prevalence and Associated Factors for Thyroid Dysfunction Among Patients On Targeted Therapy for Cancers: A Single-Center Study from Thailand.
Chawalitmongkol K; Maneenil K; Thungthong P; Deerochanawong C
J ASEAN Fed Endocr Soc; 2023; 38(2):77-85. PubMed ID: 38045662
[TBL] [Abstract][Full Text] [Related]
2. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
3. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
[TBL] [Abstract][Full Text] [Related]
7. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
8. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects.
Iwamoto Y; Kimura T; Dan K; Ohnishi M; Takenouchi H; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2023; 14():1221723. PubMed ID: 37583431
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
11. Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center.
Ruggeri RM; Spagnolo CC; Alibrandi A; Silvestris N; Cannavò S; Santarpia M
J Endocrinol Invest; 2023 Nov; 46(11):2399-2409. PubMed ID: 37076759
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
Yoon JH; Hong AR; Kim HK; Kang HC
Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
[TBL] [Abstract][Full Text] [Related]
13. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
[TBL] [Abstract][Full Text] [Related]
14. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
15. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
von Itzstein MS; Gonugunta AS; Wang Y; Sheffield T; Lu R; Ali S; Fattah FJ; Xie D; Cai J; Xie Y; Gerber DE
Cancer Immunol Immunother; 2022 Sep; 71(9):2169-2181. PubMed ID: 35072744
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction.
Zhang Q; Jiao X; Lai X
J Clin Endocrinol Metab; 2023 Oct; 108(11):2916-2923. PubMed ID: 37183427
[TBL] [Abstract][Full Text] [Related]
17. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.
Brilli L; Danielli R; Campanile M; Secchi C; Ciuoli C; Calabrò L; Pilli T; Cartocci A; Pacini F; Di Giacomo AM; Castagna MG
J Endocrinol Invest; 2021 Aug; 44(8):1719-1726. PubMed ID: 33367977
[TBL] [Abstract][Full Text] [Related]
18. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
[TBL] [Abstract][Full Text] [Related]
19. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
20. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.
Campredon P; Mouly C; Lusque A; Bigay-Game L; Bousquet E; Mazières J; Caron P
Presse Med; 2019 Apr; 48(4):e199-e207. PubMed ID: 31005502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
